Research on Lipodystrophy & Other Metabolic Complications

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1997-2000

See also: Lipodystrophy Basics

Show Archived (Historical) Articles

2008

Tesamorelin for Fat Accumulation (May/June 2008)
52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
In Positively Aware, from Test Positive Aware Network
U.S. Study Confirms Long-Term Use of AZT, d4T Result in Lipoatrophy (May 27, 2008)
From aidsmap.com
Taking a Half Dose of d4T Doesn't Reduce Fat Loss (April 16, 2008)
From aidsmap.com
Connection Found Between Belly Fat and Dementia (March 27, 2008)
From Project Inform
Genetics May Protect Some From Lipoatrophy (March 18, 2008)
From aidsmap.com
Study Looks at How Much Fat a Person Can Lose Without Noticing It (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
HIV/HCV-Coinfected Patients Appear More Likely Than HIV-Monoinfected Patients to Develop Insulin Resistance After Initiating HAART (February 5, 2008)
From The Body PRO
Body Fat Changes Becoming Less Common as HIVers Use Fat-Friendlier Meds, Study Finds (January 23, 2008)
In HIV Medicine

2007

Study Suggests Drug Can Reduce Abdominal Fat in HIVers Taking HIV Meds (October 31, 2007)
In aidsmap.com
ICAAC: Gains in Limb Fat and CD4 Counts Continue Three Years After Switching From d4T to Tenofovir (September 21, 2007)
From aidsmap.com
Increased Fat Consumption Observed in People With HIV With High Cholesterol (August 22, 2007)
From aidsmap.com
Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society
Switching to Thymidine-Sparing Regimens Successful (July 25, 2007)
Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Protein Buildup May Be Linked to Fat Gain in HIVers on Protease Inhibitors, Researchers Say (July 18, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Study Shows TH9507 May Help Treat HIV-Related Fat Gain (Summer 2007)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Testosterone Levels, Fat Free Mass, Increases Differ According to HIV Drugs Taken (June 4, 2007)
From aidsmap.com
Canadian Study Finds Bio-Alcamid Safe, Effective for Facial Lipoatrophy (May 22, 2007)
From aidsmap.com
Study May Disprove Link Between HIV/Hep C Coinfection and Some Metabolic Problems (May 21, 2007)
A pair of new U.S. studies appears to contradict long-held concerns that HIV/hepatitis C-coinfected people have a higher risk of diabetes and lipoatrophy (fat loss).
From aidsmap.com
Study Casts Doubt on Glitazones as Lipoatrophy Treatment (May 8, 2007)
From AIDSMeds.com
Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
An Interview With Steven Grinspoon, M.D. (February 26, 2007)
Dr. Grinspoon, presented the results of a large trial looking at the effects of a growth hormone releasing factor analog on HIV-associated abdominal fat accumulation .
Metabolic Syndrome as Common in HIV-Negative as in HIV-Positive Individuals (February 15, 2007)
From aidsmap.com

2006

FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration
Waist Size No Different in HIV-Infected Men on HAART Than in HIV-Uninfected Men (November 15, 2006)
From aidsmap.com
Comparing the Effects of Rosiglitazone, Pravastatin, Recombinant Human Growth Hormone and Combinations Thereof on HIV-Associated Lipodystrophy (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Recombinant Human Growth Hormone Produces Pronounced and Durable Reductions in Visceral Adipose Tissue (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Metabolic Complications of HIV Therapy (September 2006)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Initiation of HAART May Increase Free Testosterone Levels and Fat-Free Mass (August 17, 2006)
In XVI International AIDS Conference
Metabolic Complications at the XVI International AIDS Conference: Part 1 -- An Overview of New Data (August 17, 2006)
In XVI International AIDS Conference
Metabolic Complications at the XVI International AIDS Conference: Part 2 -- Lipids (August 17, 2006)
In XVI International AIDS Conference
Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
HIV JournalView: Metabolic Complications and HAART: Some New Answers and Many More Questions (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO

2005

Benefit of Rosiglitazone or Metformin for Lipodystrophy Still Unclear (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says (November 3, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com
Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Five Ways to Tackle Toxicity (or the Ant, the Spider, and the Bee): 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2005)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care

2004

Fiber May Help Prevent Lipodystrophy (September 20, 2004)
Weight-bearing exercise and less smoking is also found to reduce the chances that men with HIV will develop fat around their waists.
To read PDF, click here
From PositiveWords
HIV JournalView: Exogenous Growth Hormone, an Expensive (and Questionable) Fat Accumulation Treatment (September 2004)
From The Body PRO
HIV JournalView: Using Suction-Assisted Lipectomy to Treat Buffalo Hump (September 2004)
From The Body PRO
Metabolic Complications of HIV and Its Therapies (July 16, 2004)
A detailed overview of recent research.
In The XV International AIDS Conference
A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
Kidney Fat Could Be a Predictor of Lipodystrophy (July 6, 2004)
Researchers use ultrasound to gauge the likelihood a patient will develop lipodystrophy after starting HAART, or whether a treatment switch will improve existing lipodystrophy.
From aidsmap.com
Vitamins and Exercise May Help HIV-Related Metabolic Disorders (June 19, 2004)
In The Advocate
Vitamins, Exercise May Help Metabolic Disorders (June 16, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Lipid-Lowering Drug Helps Triglyceride Levels in HIVers With Lipodystrophy (June 2004)
A daily dose of fenofibrate is found to lower abnormally high triglyceride levels in HIV-positive people with lipodystrophy, without causing any severe side effects.
In American Journal of Medical Science
Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Canadian Company Reports Promising Lipodystrophy Treatment (April 19, 2004)
ThGRF has been found to reduce abdominal fat in HIV-infected patients without adversely affecting blood-glucose levels.
From aidsmap.com
Can Atazanavir Reverse Body Fat Changes? (April 8, 2004)
Anecdotal evidence recently reported in the journal AIDS suggests that atazanavir (Reyataz) may treat lipodystrophy.
From aidsmap.com
Diabetes Drug and Exercise Help Reduce Heart Disease Risk and Improve Body Shape in HAART Patients (March 12, 2004)
From aidsmap.com
Complications of Antiretroviral Therapies and HIV (March 2004)
An examination of diabetes, kidney disease, bone problems and hypertension research from the February Retrovirus conference.
In Hopkins HIV Report
CROI 2004 Recap: Metabolic Complications (March 2004)
David Wohl, M.D., reviews research highlights from the 11th Conference on Retroviruses and Opportunistic Infections.
In HEPP Report, from Brown Medical School
Lipodystrophy & Metabolic Complications (March 2004)
A summary of several research highlights on metabolic complications from February's 11th Conference on Retroviruses and Opportunistic Infections.
In Hopkins HIV Report
An Overview of the Metabolic Complications of HIV/HAART (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

2003

Fiber-, Protein-, Calorie-Rich Diet Appears to Protect Against Central Fat Gain in Men (December 11, 2003)
From aidsmap.com
High-Fiber Diet in HIV-Positive Men Is Associated With Lower Risk of Developing Fat Deposition (November 2003)
Abstract of a study in the American Journal of Clinical Nutrition.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
New Form of Liposuction Able to Reduce Buffalo Hump -- At Least in the Short Term (October 20, 2003)
A combination of liposuction and ultrasound is found to make buffalo humps smaller, but for half of the study patients the hump eventually grew back fully.
From aidsmap.com
Sublime Versus Simple Side Effect Stories (or, Forget the Adiponectin, Just Stop Smoking) -- 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (October 2003)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Dyslipidemia: Change to Tenofovir? (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Women Get More Lipodystrophy Than Men, Says Italian Study (September 10, 2003)
In this large study, women on HAART were found to be at a greater risk for developing body fat changes than men -- although men generally seemed to LOSE fat more often than women.
From aidsmap.com
Antioxidants Have Little Benefit in People With Lipoatrophy (August 29, 2003)
A combination of vitamin E, vitamin C and N-acetylcysteine has positive and negative health results.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
HIV-Positive Teenagers With Lipodystrophy Have Lower Growth Hormone Secretion (July 1, 2003)
Researchers conducting a small study believe they've found the first link between lipodystrophy and lack of growth hormone in children on HAART.
From aidsmap.com
New Drug Being Studied for Lipodystrophy (June 23, 2003)
The promise of TH9507, a peptide that stimulates growth hormone production.
From Canadian AIDS Treatment Information Exchange
Diabetes Risk Triples in Women on PIs (April 24, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Increased Lipodystrophy Is Associated With Increased Exposure to Highly Active Antiretroviral Therapy in HIV-Infected Children (April 15, 2003)
In Journal of AIDS
Bezafibrate Improves Glucose Uptake and Endothelial Function in HIV Patient (March 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Metabolic and Morphologic Complications in HIV Disease: What's New (March 11, 2003)
A review of recent findings on insulin resistance, body fat changes and related problems.
In The PRN Notebook
Retrovirus 2003: Management of Metabolic Complications (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Nutrition and Exercise to Manage Lipodystrophy (January 2003)
Research from the 2002 International AIDS Conference.
In Project Inform Perspective, from Project Inform
Protease Inhibitors and Atherosclerosis (January/February 2003)
In TAGline, from Treatment Action Group
Report From the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2003)
In Hopkins HIV Report
Segmental BIA: Can We Measure Lipodystrophy? (December 2002/January 2003)
Emerging data reported at the ninth annual ANSA Conference.
In Survival News, from AIDS Survival Project

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.